Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
boston blog main
deals
life sciences
national blog main
san francisco blog main
san francisco top stories
4
×
biotech
boston top stories
national top stories
new york blog main
new york top stories
boehringer ingelheim
boston
clinical trials
eli lilly
indiana blog main
indiana top stories
ipo
san diego blog main
san diego top stories
sanofi
startups
wisconsin blog main
wisconsin top stories
abbvie
acetylon pharmaceuticals
akouos
alexion pharmaceuticals
allergan
alnylam pharmaceutials
alnylam pharmaceuticals
amag pharmaceuticals
ambys medicines
amunix
anirvan ghosh
arrowhead pharmaceuticals
astrazeneca
biogen
biontech
bluerock therapeutics
What
deal
4
×
medicines
4
×
bio
companies
new
rna
abandoning
acquisitions
ago
aiming
ambys
announced
baggage
bets
big
biotech
cancer
ceo
collabs
comes
control
covid
cut
cuts
daniel
date
deadly
debuted
development
dicerna
diseases
effective
enticed
evidence
formed
free
future
gets
gilead
gilead’s
Language
unset
Current search:
medicines
×
photo
×
" san francisco top stories "
×
deal
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines